摘要
目的探讨miR-148b在非小细胞肺癌患者血清中的表达水平及其预后价值。方法选取本院确诊的非小细胞肺癌患者196例,同期选择门诊健康体检者48例作为对照组,采用逆转录实时荧光定量法测定血清miR-148b mRNA蛋白的表达。结果肺癌组miR-148b mRNA表达水平低于对照组,差异有统计学意义(P <0. 05);肺癌组miR-148b mRNA阳性率低于对照组,差异有统计学意义(P <0. 05); miR-148b mRNA的表达率与年龄、肿瘤最大径、肿瘤数目,相关性不明显,差异无统计学意义(P> 0. 05);与病理学分级、TNM分期、淋巴血管间隙浸润、淋巴结转移、复发相关明显,且病理学分期越高、TNM分期越高、淋巴血管间隙浸润、淋巴结转移和复发患者的miR-148b mRNA阳性表达率越低,差异有统计学意义(P <0. 05); miR-148b表达阳性组3年生存率及生存期均明显高于miR-148b阴性组,差异有统计学意义(p <0. 05)。结论 miR-148b在非小细胞肺癌患者血清中的表达量低于健康人群,miR-148b在非小细胞肺癌的发生发展过程中起抑制作用; miR-148b阳性表达者可能获得较好的预后。
Objective To investigate the expression of miR-148b in serum of non-small cell lung cancer patients and its prognostic value.Methods In this study,196 NSCLC patients diagnosed in our hospital(the NSCLC group)and 48 healthy individuals(the control group)in department of physical examination were selected during the same period.The expression of miR-148b in serum was measured by real time fluorescent quantitative reverse transcription.Results The expression of miR-148b in mRNA in the NSCLC group was lower than that in the control group(P<0.05).The positive rate of miR-148b in mRNA in the NSCLC group was lower than that in the control group(P<0.05).The expression of miR-148b in mRNA showed no significant correlation with age,tumor diameter or tumor number(P>0.05),while the positive expression of miR-148b in mRNA was positively correlated with pathological grade,TNM staging,lymphatic vascular space invasion,lymph node metastasis and recurrence(P<0.05).The 3-year survival rate and survival term in the miR-148b positive group were significantly higher than those in the miR-148b negative group(P<0.05).Conclusion The expression of miR-148b in serum of NSCLC patients is lower than that in healthy individuals,which suggests that miR-148b can inhibit the development and progression of NSCLC.The positive expression of miR-148b may have a better prognosis.
作者
吴洲清
毛明
陈家宽
WU Zhou-qing;MAO Ming;CHEN Jia-kuan(Department of Thoracic and Cardiovascular Surgery, Central South Hospital of Wuhan University, Wuhan, Hubei 430071, China)
出处
《临床肺科杂志》
2019年第1期83-86,共4页
Journal of Clinical Pulmonary Medicine
作者简介
通信作者:陈家宽,E-mail:jiakuanchen6136@sina.com
